TargetBeta
TACR1
tachykinin receptor 1 · also SPR, NK1R, NKIR, TAC1R · Tachykinin receptors
5 programs in company-led studies act on TACR1, from 5 companies: 3 in phase 3, 1 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (4 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| Aprepitantrule | Merck | phase 4 | 271 running | – | ChEMBL |
| tradipitantrule | Vanda Pharmaceuticals | phase 3 | 193 running | – | NCIt |
| elinzanetantrule | Bayer | phase 3 | 242 running | TAC3, TACR3 | NCIt |
| fosnetupitantrule | Helsinn Healthcare | phase 3 | 20 running | – | NCIt |
| HRS5580 | Jiangsu HengRui Medicine | phase 2 | 21 running | – | the company's pipeline |
Conditions their studies are in
- Vomiting, 3 programs
- Nausea, 2 programs
- Postoperative Nausea and Vomiting, 2 programs
- Pruritus, 2 programs
- Depressive Disorder, Major, 1 program
- Dermatitis, Atopic, 1 program
- Gastroparesis, 1 program
- Hot Flashes, 1 program
- Motion Sickness, 1 program
- Schizophrenia, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Dec 2026HRS5580 · Jiangsu HengRui Medicine · phase 2 · NCT07709897
- Dec 1, 2026tradipitant · Vanda Pharmaceuticals · phase 3 · NCT07446439
- Jan 22, 2027elinzanetant · Bayer · phase 3 · NCT07762287
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.